BiotechTube
Home/Pipeline/BIO101 (20-hydroxyecdysone)

BIO101 (20-hydroxyecdysone)

Sarcopenia

Phase 3Preparing for Phase 3 trial; Phase 2 completed with positive mobility data.

Key Facts

Indication
Sarcopenia
Phase
Phase 3
Status
Preparing for Phase 3 trial; Phase 2 completed with positive mobility data.
Company
Biophytis, Biophytis

About Biophytis

Biophytis is a clinical-stage biotech focused on geroscience, aiming to treat age-related diseases by targeting the hallmarks of aging. Its core strategy revolves around three pillars: a proprietary AI-accelerated longevity research platform, the advanced Phase 3-ready program BIO101 for sarcopenia, and a parallel program for BIO101 in obesity as a combination therapy with GLP-1 agonists. The company has secured strategic partnerships and funding to advance its pipeline, including a landmark joint venture in Asia and an expanded AI collaboration with LynxKite.

View full company profile

About Biophytis

Biophytis is a clinical-stage biotech focused on geroscience, aiming to treat age-related diseases by targeting the hallmarks of aging. Its core strategy revolves around three pillars: a proprietary AI-accelerated longevity research platform, the advanced Phase 3-ready program BIO101 for sarcopenia, and a parallel program for BIO101 in obesity as a combination therapy with GLP-1 agonists. The company has secured strategic partnerships and funding to advance its pipeline, including a landmark joint venture in Asia and an expanded AI collaboration with LynxKite.

View full company profile

Therapeutic Areas

Longevity / GeroscienceSarcopeniaObesityOphthalmology

Other Sarcopenia Drugs

DrugCompanyPhase
DT-201Dystrogen TherapeuticsPreclinical
Sarcopenia Drug CombinationCentenara LabsDiscovery